Taro Bannai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Taro Bannai has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Tomonari Seki
3 shared publicationsYasushi Shiio
3 shared publicationsAya Midori Tokumaru
Department of Diagnostic Radiology, TMIG, Tokyo, Japan
2 shared publications- Fumio Suzuki
Department of Diagnostic Radiology, TMIG, Tokyo, Japan
2 shared publications - Keiko Hatano
Department of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan
2 shared publications Kenji Ishii
Integrated Research Initiative for Living Well with Dementia (IRIDE), TMIG, Tokyo, Japan; Research Team for Neuroimaging, TMIG, Tokyo, Japan
2 shared publications
Latest Publications
- Open Access
- 11 April 2026
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (6) , 100567
ATNIVS biomarker heterogeneity in real-world patients receiving lecanemab
- 11 April 2026
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (6) , 100567
Open AccessATNIVS biomarker heterogeneity in real-world patients receiving lecanemab
- Open Access
- 4 April 2026
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (6) , 100562
Amyloid-related imaging abnormalities in Japanese patients with Alzheimer’s disease treated with Lecanemab: A real-world study
- 4 April 2026
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (6) , 100562
Open AccessAmyloid-related imaging abnormalities in Japanese patients with Alzheimer’s disease treated with Lecanemab: A real-world study
- 4 February 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (4) , 349-350
Reversible Parkinsonism With Recovery of 123I-Ioflupane DAT‑SPECT After Treating Rheumatoid Meningitis
We report reversible parkinsonism in rheumatoid meningitis with normalization of 123 I-ioflupane DAT-SPECT after immunotherapy. A previously independent 42-year-old man presented with fever, encephalopathy, focal seizures, and akinetic-rigid parkinsonism. MRI showed pachy/leptomeningeal enhancement with sulcal FLAIR hyperintensity; CSF revealed lymphocytic pleocytosis and elevated protein with negative infectious studies. High-dose intravenous methylprednisolone followed by taper led to rapid improvement. Baseline DAT-SPECT showed reduced striatal uptake, which recovered on follow-up in parallel with symptom resolution and reductions in intrathecal anti-CCP index and CSF IL-6, supporting autoimmune, reversible presynaptic dopaminergic dysfunction.
- 4 February 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (4) , 349-350
Reversible Parkinsonism With Recovery of 123I-Ioflupane DAT‑SPECT After Treating Rheumatoid Meningitis
We report reversible parkinsonism in rheumatoid meningitis with normalization of 123 I-ioflupane DAT-SPECT after immunotherapy. A previously independent 42-year-old man presented with fever, encephalopathy, focal seizures, and akinetic-rigid parkinsonism. MRI showed pachy/leptomeningeal enhancement with sulcal FLAIR hyperintensity; CSF revealed lymphocytic pleocytosis and elevated protein with negative infectious studies. High-dose intravenous methylprednisolone followed by taper led to rapid improvement. Baseline DAT-SPECT showed reduced striatal uptake, which recovered on follow-up in parallel with symptom resolution and reductions in intrathecal anti-CCP index and CSF IL-6, supporting autoimmune, reversible presynaptic dopaminergic dysfunction.
- Open Access
- 19 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 801
Anti-GQ1b Antibody Syndrome: A Clinician-Oriented Perspective on Diagnostics, Therapy, and Atypical Phenotypes—With an Illustrative 16-Case Institutional Series
Anti-GQ1b antibody syndrome (AGABS) unifies triad-defined Miller Fisher syndrome (MFS), Bickerstaff brainstem encephalitis (BBE), and the ophthalmoplegic variant of Guillain–Barré syndrome (GBS-O) under a post-infectious immune mechanism centered on IgG to disialosyl gangliosides. The spectrum also encompasses triad-minus phenotypes—acute ophthalmoparesis without ataxia, acute vestibular syndrome, optic involvement, and acute sensory-ataxic neuropathy. A molecular-mimicry model with complement-mediated nodal/paranodal dysfunction explains severe early deficits despite bland limb nerve conduction studies (NCSs), the cranial/proprioceptive predilection, and generally favorable treatment responsiveness to immunotherapy. In practice, a serology-first strategy, complemented by targeted electrophysiology—blink and H-reflex testing, and, where feasible, paired SEP–ABR showing a literature-supported dissociation (normal ABR with impaired median-nerve cortical SEPs), which, in our series, was documented in one illustrative BBE case—and by structured neuro-otologic examination, mitigates the “normal-NCS trap” and enables timely treatment. Intravenous immunoglobulin (IVIg) is first-line; plasma exchange (PLEX) is an alternative in severe or IVIg-ineligible cases; and intravenous methylprednisolone (IVMP) may be added selectively for central/optic-weighted phenotypes without routine oral taper. We consolidate actionable diagnostic and therapeutic steps and examine them in an institutional series of 16 consecutive seropositive patients (2015–2025): all were anti-GQ1b-positive with frequent GT1a co-reactivity; most reported an antecedent infection—typically upper respiratory, less often gastrointestinal—within the two weeks before onset; limb NCSs were often nondiagnostic whereas reflex/evoked-potential studies were informative; two required intubation in addition to IVIg; outcomes were generally favorable with early immunotherapy. The practical message: order anti-GQ1b at first contact, pair targeted electrophysiology with neuro-otology, and treat early to exploit reversible nodal/paranodal dysfunction.
- 19 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 801
Open AccessAnti-GQ1b Antibody Syndrome: A Clinician-Oriented Perspective on Diagnostics, Therapy, and Atypical Phenotypes—With an Illustrative 16-Case Institutional Series
Anti-GQ1b antibody syndrome (AGABS) unifies triad-defined Miller Fisher syndrome (MFS), Bickerstaff brainstem encephalitis (BBE), and the ophthalmoplegic variant of Guillain–Barré syndrome (GBS-O) under a post-infectious immune mechanism centered on IgG to disialosyl gangliosides. The spectrum also encompasses triad-minus phenotypes—acute ophthalmoparesis without ataxia, acute vestibular syndrome, optic involvement, and acute sensory-ataxic neuropathy. A molecular-mimicry model with complement-mediated nodal/paranodal dysfunction explains severe early deficits despite bland limb nerve conduction studies (NCSs), the cranial/proprioceptive predilection, and generally favorable treatment responsiveness to immunotherapy. In practice, a serology-first strategy, complemented by targeted electrophysiology—blink and H-reflex testing, and, where feasible, paired SEP–ABR showing a literature-supported dissociation (normal ABR with impaired median-nerve cortical SEPs), which, in our series, was documented in one illustrative BBE case—and by structured neuro-otologic examination, mitigates the “normal-NCS trap” and enables timely treatment. Intravenous immunoglobulin (IVIg) is first-line; plasma exchange (PLEX) is an alternative in severe or IVIg-ineligible cases; and intravenous methylprednisolone (IVMP) may be added selectively for central/optic-weighted phenotypes without routine oral taper. We consolidate actionable diagnostic and therapeutic steps and examine them in an institutional series of 16 consecutive seropositive patients (2015–2025): all were anti-GQ1b-positive with frequent GT1a co-reactivity; most reported an antecedent infection—typically upper respiratory, less often gastrointestinal—within the two weeks before onset; limb NCSs were often nondiagnostic whereas reflex/evoked-potential studies were informative; two required intubation in addition to IVIg; outcomes were generally favorable with early immunotherapy. The practical message: order anti-GQ1b at first contact, pair targeted electrophysiology with neuro-otology, and treat early to exploit reversible nodal/paranodal dysfunction.
- 1 May 2019
- Published by Elsevier in The Lancet
- Vol. 393 (10185) , e40-E40
A pain in the neck: calcific tendinitis of the longus colli muscle
- 1 May 2019
- Published by Elsevier in The Lancet
- Vol. 393 (10185) , e40-E40
A pain in the neck: calcific tendinitis of the longus colli muscle